Highest-materiality recent filing
UHS Q1 net income $348.7M ($5.65 EPS), revenue +9.6% to $4.5B
Net income attributable to UHS $348.7M ($5.65 diluted EPS) vs $316.7M ($4.80) in Q1 2025.
UHS adds $900M in new credit facilities; $400M delayed draw term loan to fund Talkspace acquisition
Added $200M incremental revolving loan, $300M incremental term loan, and $400M delayed draw term loan on April 22, 2026.
UHS to acquire Talkspace for $5.25/share ($835M EV) to expand virtual behavioral health
UHS will pay $5.25 per share in cash; enterprise value ~$835M, financed via existing revolving credit facility.
UHS gets new trial vacating $500M punitive damages verdict in Nevada lawsuit
Judge granted new trial based on juror misconduct; entire $500M punitive verdict expected to be vacated.
UHS subsidiary hit with $500M punitive damages verdict; expects reduction to ~$14M under Nevada law
Jury awarded $4.7M compensatory and $500M punitive damages against UHS of Delaware, Inc.
UHS Q1 2025 EPS soars to $4.80 from $3.82; revenue +6.7% to $4.1B
Net income $316.7M ($4.80 diluted EPS) vs $261.8M ($3.82) in Q1 2024; adjusted EPS $4.84 vs $3.70.
UHS Q3 net income jumps 55% to $258.7M, EPS $3.80 vs $2.40; revenue up 11.2%
Adjusted diluted EPS of $3.71, up from $2.55 in Q3 2023; revenue rose to $3.96B from $3.56B.
UHS subsidiary's punitive damages reduced to $120M from $475M; appeal planned
Trial court ordered remittitur of punitive damages from $475M to $120M on Oct 10, 2024.
UHS issues $1B in senior secured notes, refinances $2.2B term loan facility
$500M of 4.625% notes due 2029 and $500M of 5.050% notes due 2034 issued on Sep 26, 2024.
UHS faces $360M jury verdict in Cumberland sexual misconduct case; punitive expected to be cut
Jury awarded $60M compensatory, $180M trebled damages (VCPA), $120M punitive against Cumberland and Dr. Davidow.
UHS Q2 EPS $4.26 vs $2.42 YoY; raises 2024 guidance; adds $1B to buyback
Q2 net income $289.2M ($4.26 diluted EPS) vs $171.3M ($2.42) YoY; adjusted EPS $4.31.
UHS Q1 net income $261.8M ($3.82 EPS); revenue +10.8% to $3.84B
Reported EPS $3.82 vs $2.28; adjusted EPS $3.70 vs $2.34. Revenue $3.844B +10.8% YoY.
UHS subsidiary hit with $535M jury verdict in patient sexual assault case
Pavilion Behavioral Health System found liable for sexual assault of minor patient by another minor patient in 2020.
UHS Q4 revenue $3.704B, adj EPS $3.13; FY 2024 guidance adj EPS $13-14
Q4 2023 net revenues $3.704B (+7.4% YoY); adjusted EPS $3.13 vs $3.02 in Q4 2022.
CMS approves Nevada Medicaid payment program; UHS estimates $158M net reimbursements in 2024
CMS approved the Medicaid managed care component of Nevada SDP effective Jan 1, 2024 for UHS facilities.
UHS Q1 2023 net income $163.1M ($2.28 EPS); revenue $3.468B, up 5.3% YoY
Adjusted EPS $2.34 vs $2.15 YoY; adjusted EBITDA $421.1M vs $379.5M.
UHS appoints Edward Sim as EVP & President, Acute Care, succeeding retiring Marvin Pember
Marvin Pember, EVP and President, Acute Care, plans to retire after a transition period.
UHS slashes FY2022 guidance; Q2 adjusted EPS seen at $2.05-$2.15
Q2 2022 adjusted EPS estimated at $2.05-$2.15, well below prior expectations due to lower acute care COVID volumes.
UHS adds $700M incremental term loan, extends maturity to 2026
Ninth Amendment to credit agreement adds $700M incremental Tranche A term loan due Aug 24, 2026.
UHS Q1 adjusted EPS $2.15 vs $2.44 YoY; revenue up 9.3% to $3.293B
Reported net income $153.9M ($2.02 diluted) vs $209.1M ($2.43) in Q1 2021; adjusted net income $163.5M ($2.15).
On May 18, 2026, Matthew J. Peterson, Executive Vice President of the Company and President, Behavioral Health, who has been with the Company since 2019, submitted his resignation from his position with the Company, effective June 19, 2026
Lawrence S. Gibbs, a member of the Board of Directors (“Board”) of Universal Health Services, Inc. (“UHS”), has informed the Board that he has accepted a new employment opportunity which will restrict his ability to serve on UHS’ Board.
Edward H. Sim, the newly appointed Executive Vice President of the Company and President, Acute Care, whose employment commenced on December 5, 2022.
Marvin G. Pember, Executive Vice President of the Company and President, Acute Care, who has been with the Company since 2011, informed us of his intention to retire from his position after a transition period following the commencement of employment of Edward H. Sim, the newly appointed Executive Vice President of the Company and President, Acute Care, whose employment commenced on December 5, 2022.
On October 21, 2022, Marvin G. Pember , Executive Vice President of the Company and President, Acute Care, who has been with the Company since 2011, informed us of his intention to retire from his position after a transition period following the commencement of employment of Edward H. Sim, as described below.
On October 21, 2022, Marvin G. Pember , Executive Vice President of the Company and President, Acute Care, who has been with the Company since 2011, informed us of his intention to retire from his position after a transition period following the commencement of employment of Edward H. Sim, as described below.
On September 21, 2022, the Board of Directors of the Company appointed Nina Chen-Langenmayr to serve as a Class III Director of the Company.
Max materiality 0.90 · Median 0.50 · Most common event earnings